








→ Aminoglycosides also binds to A-site → interfere w ribo. assembly by causing distortion

A-site → P-site translocation

Macrolides




P.T = present in 50S subunit

Peptidyl transferase


↓

add. of new A.A to growing peptide chain

Linezolid



Fidaxomicin = (macrolide)



clindamycin like Aminoglyc. but belong to Lincosamide.


Do watch lecture on Pharmacology youtube

CELL-WALL INHIBITOR — PENICILLINS (dividing microorg.)


- To be max. effective - cell be in actively proliferating
- Member of this family differ from one another in R-subst. (of 6-AMINO PENICILLANIC ACID RESIDUE)
- This side chain affect - (i) spectrum & stability to stomach acid
- (ii) cross-hypersens. (iii) susceptibility to β -lactamases.
- These're bactericidal & work in Time-dep. fashion.

MECHANISM

Penicillin = 1928.




ANT-BACTERIAL SPECTRUM



(HNN-D)

ADRS

Do watch lecture on Pharmacology study youtube



Resistance

- absence of peptidoglycan wall (e.g. *Mycoplasma pneumoniae*)
- cell wall impermeable to drugs.

(*Mycoplasma pneumoniae* has cell wall (mycoid))

↓
doesn't contain cell wall.

Mechanisms

B-lactamase Activity

- B-lactamase hydrolyse (Breaks) the cyclic amide bond of B-lactam ring
- produce by chromosomes or acquired by transfer of plasmids
- Gram +ve → secrete Extracellular B-lac.
- Gram -ve → periplasmic spaces

↓ use permeability to drug

presence of efflux pumps e.g. in *K. pneumoniae*


Altered PBPs

modified PBPs

↓
lower affinity for B-lactam.

Do watch lecture on Pharmacology - study youtube

Thiazolidine ring (5-memb)



KINETICS

Routes of adm


- [ampicilli + sulbac.]
 - [ticarci + clavini]
 - [piper + Tazobac]
 - [nafcilli, Oxacillin]
- must be IV / IM
Tonzol (Brand)
- pen V, amoxi & didoxacillin avail as oral; ampicillin
 - amoxicillin + clavinate - oral
 - procain PenG & Benzathine PenG - IM - depot form

Absorp.

- incomp. abs. after oral adm.
- food ↓ abs. of as penicillin-resis-penicillin as ↓ gastric emptying = ↓ time in stomach = destroy by stomach acid
- ✓ - empty stomach preferred.

Distribu

- Distribute well
- cross-placenta → teratogenic
- penetrate in bones or CSF (in inflamed condition of meninges)
- NOT much penetrate/enter in prostate



Excre:- Through Kidney.

PROBENECID inhibit secretion of penicillin by competing for active tubular secre. via organic acid transporter


- Also excreted in Breast milk -

~~BF avoid~~

CEPHALOSPORINS

Most of them are produced semi-syn by chemical attachment of side chain to 7-aminocephalosporanic acid. Have same MOA & same MOA. However, they tend to be more resistant than penicillins to certain β -lactamases.

GENERATIONS



ADVANCED GENER.

- Ceftriaxone (broad spec) (IV as prod. (ceftriaxone fosamil))
- Indicated for MRSA, CAP, complicated skin infec.
- Binds to PBP2a (found in MRSA) and PBP2x (strep. pneum.)
- gram -ve coverage similar to ceftriaxone
- * Cephalosporins susceptible to ESBLs (E. coli, K. pneumoniae), NOT susceptible to hydrolysis by S. penicillares

KINETICS

ADMINIS

- must be given IV/Im except those as previously told.

Distribution

- Distribute well
- penetrate CSF, regardless of inflamm. (cefotaxime, ceftiax)
- cefazolin ($t_{1/2}$ 1.8 hr) use as single prophylactic agent (dose) prior to surgery (*S. aureus*).
 - ↳ esp. orthopedic surgery due to ability to penetrate bones.
- All of them cross → Placenta

Elimination

- ↓
Kidney.
(GFR + Secretion)
exception
ceftriaxone
↓
(Bile)

ADRS

allergic rxn

Diarrhea

(pt is penicillin induced disease - ST-syndrome or toxic epidermal necrosis)

Do watch lecture on Pharmaco-study youtube

CARBAPENEMS — β -lactam antibiotics

- In its structure sulfur atom has been externalized from Thiazolidine ring and has been replaced by C atom.
- compounded w/ cilastatin to protect it from metab. by renal dehydropeptidase (This enzyme produces ^{nephro}toxic inactive metab. in proximal brush border)

Spectrum

Resist β -lactamases except

Metallo- β -lactamases

Imipenems/Mero/Dori

• +ve cocci

S. aureus

S. epidermidis

Step. A, B, C

Step. pneumoniae

Enterococcus faecalis

+ve bacilli — *Listeria*, M.O.

-ve cocci — *Neisseria*, gonorr.

Neisseria, meningitis

-ve rods

Acinetobacter, *Citrobacter*,

Enterobacter (species)

• *E. coli* • *H. influenza*

• *Klebsiella* sp. • *Proteus* sp.

• *Gardnerella vaginalis*

• *Providencia* sp.

• *P. aeruginosa* • *Salmonella*

• *Serratia*

Anaerobic org.

Clostridium

Peptococcus

Peptostreptococcus

Bacteroides

Fusobacterium

Other

— *Actinomyces*

— *Nocardia* sp.

Kinetics

• Imip/cilastatin &

meropenem are

adm — IV

• penetrate CSF (when inflamed)

• Meropenem reaches therap.

level even without inflam.

• Ertapenem — IV/IM OD

• Doses must be adj in renal insufficiency

ADRs

• N/V/D.

• eosinophillaz less common than other

• Neutropenia

• High level = seizures

This drug lack coverage against *P. aero*, *Enterococ*, *Acinetob.*

Anticonom —

MONOBACTAMS

• β -lactam antibio, but rings are not fused to each other

• Directed primarily against (gr. -ve) *Enterobacteriaceae* & *P. aerog.*

• lack activity against gr. +ve. (like 2nd gen. cephs)

• Resist β -lactamases except ESBLs.

• IV/IM • Accumulate in renal insuff.


⇒ Relatively Non-toxic, may cause Phlebitis, skin rash, abnor. LFT

⇒ Safer for pt. allergic to penicillins, cephalos or carbapenems.

B-LACTAMASE INHIBITORS

* contain β -lactam ring — NOT significant antibacterial activity or adrs.

* They bind & inactivate β -lactamases thus protecting antibiotics that're normal substrate for these enzyme.



★-

POLYMYXINS

- ★- are cation polypeptides — binds to phospholipids on bac cell membrane of gr^{-ve} bac.
- ★- Detergent like effect — disrupt cell mem. integrity → cellulose compon. leaks. ↓ death.
- ★- conc. dep. bactericidal agent

Spectrum

↓
P. aeruginosa E. coli K. pneumoniae Acinetobacter sp. Enterobacter sp.

Resistance: - alteration in cell mem of lipid polysaccharide (proteins & serratia)

Forms < B — avail in parenteral, enteral, opth, otic & topical prep.
(oral or tube feeding)
E (colistin) — avail only as pro-drug (colistimethate Na⁺)
↓
IV, inhaler via nebulizer

Systemic Adminis.

- ★- Now-a-days commonly used as salvage therapy in MDI (infections). ↑ risk of nephro & neurotox. ↓ muscle strength, weakness.
- careful dosing & monitoring of adr = maximize safety & efficacy.

FOSFOMYCIN

- ★- Bactericidal syn. derivative of phosphonic acid
- ★- Inhibitor of enzy UDP-N-acetylglucosamine enolpyruvyl transferase

Fosfo ⊖ ↓

catalyze 1st step in peptidoglycan synthesis

Therap. use :- UTI (caused by E. coli or E. faecalis) OD

as it maintain high conc. in urine.

- NO cross resis. w/ other antimicro.
- rapidly abs. after oral adm.
- Distrib. well to kidney, bladder & prostate (1g 1 day 1 time)
- excreted well in active form in urine & feces.

ADRs: Diarrhea, vaginitis, Nausea & headache.

Character? MOA

VANCOMYXIN

Inhibit cell wall phospholipid as well as peptidoglycan polymer.

DAPTOMYCIN

Cause rapid depolarization of cell mem., inhibit intracellular syn. of DNA, RNA & protein

TELAVACIN

Inhibit cell wall synthesis, disrupt cell memb.

DYNAMIC

Time-dependent bactericidal

conc. dep. Bactericidal

conc. dep. -cidal

Common Spectrum

the (*S. aureus* [including MRSA], *Strep pyogenes*, *S. agalactiae*, *Penicillin resis S. pneumoniae*, *Corynebacterium jeikeium*, *Vanco. -susceptible Enterococcus faecalis* & *E. faecium*.

Unique Spectrum

Clostridium difficile (oral only) *g+ve*

Vanco. resis. E. faecalis and *E. faecium* (VRE)

Vanco. resis. enterococci (VRE)

Route

IV/PO

IV

IV


Typical adm. Time

60-90 min IV infusion

2 min IV push
30 min IV infus.

60 min IV infus.


Kinetics



- Renal elimination
- $t_{1/2}$: 6-10 hr
- Dose adj based on renal func. & serum trough level

- Renal elim
- $t_{1/2}$: 7-8 hr
- Dose adjustment on renal func.

- Renal elim
- $t_{1/2}$: 7-9 hr



Unique ADPs

Infusion related rx due to histamine release: fever, chills, phlebitis, flushing (Red-man syndrome)

- Dose-related oto-nephrotoxicity

• Myalgias, ↑ hepatic transaminases & creatinine phosphokinase (check weekly)
• Rhabdomyolysis (consider holding HMG-CoA red. inhib. statin, while on therapy)

• Taste disturbance
• foamy urine, QTc prolongation
• interfere w/ coag. labs (PT/INR, aPTT, ACT)
NOT recommended in pregnancy.

(Taste also in ACEI)

Key learning points:

• DOC - Severe MRSA

• oral form used only for *C. difficile* Resistance:

• Plasmid-mediated changes in drug permeability

• ↓ Vanco binding to receptor mol.

• monitor serum trough conc. for safety & efficacy

• Dapto. inactivated by pulmonary surfactants

• never used in pneumonia

Reduce surface tension at air-liquid interface
↓ P.S = complex of lipid & protein found in fluid lining alveolar surface of lungs

• Caution in pt w/ renal dysfunction (crackles/min)

• necessary coag. lab. should be drawn just prior to Telavancin dose to avoid interaction